CION Ameerpet
Waldenström macroglobulinaemia is a rare, slow-growing non-Hodgkin lymphoma in which B-cells overproduce IgM antibody. This guide explains its symptoms, how it is diagnosed, and how CION's haematology team decides when to monitor and when to treat.
Waldenström macroglobulinaemia (WM) is a rare, slow-growing type of B-cell non-Hodgkin lymphoma. It is the clinical form of what pathologists call lymphoplasmacytic lymphoma — an abnormal growth of B-lymphocytes in the bone marrow that behave partly like lymphoma cells and partly like antibody-making plasma cells. These cells pour out large amounts of one specific antibody, IgM, which is why WM is sometimes described simply as an IgM lymphoma.
The two things that make WM distinctive are its slow (indolent) pace and the effects of that excess IgM protein. IgM is a large antibody, and when there is too much of it the blood can literally thicken — a state called hyperviscosity — which drives many of the symptoms. Because WM usually develops over years rather than weeks, many people are diagnosed after a routine blood test picks up a raised protein level before any symptoms appear.
This guide walks through the symptoms, how WM is diagnosed, the treatment options described by mechanism, and the outlook. For specific drug regimens, see our Lymphoma Treatment in Hyderabad page, and to meet the team see our best lymphoma doctors in Hyderabad.
The large majority of Waldenström macroglobulinaemia cases carry a mutation in a gene called MYD88 (most often the L265P variant). Testing for this mutation on a bone-marrow sample supports the diagnosis and helps distinguish WM from other B-cell disorders that can look similar. (Source: NCCN and ESMO clinical practice guidelines for Waldenström macroglobulinaemia / lymphoplasmacytic lymphoma.)
WM symptoms come from two sources: the lymphoma cells crowding the bone marrow, and the thick IgM protein circulating in the blood. Many people have no symptoms at diagnosis.
Tiredness and breathlessness from anaemia (low red cells) are the most common. Others include unexplained weight loss, drenching night sweats, low-grade fevers, and swollen lymph nodes or an enlarged spleen. Frequent infections or easy bruising can occur when normal blood cells are reduced.
When IgM is very high the blood thickens, causing headaches, blurred or disturbed vision, dizziness, nosebleeds, ringing in the ears or confusion. This is called hyperviscosity syndrome and should be assessed urgently — it can be relieved quickly by removing IgM from the blood.
Some people develop peripheral neuropathy — numbness, tingling or weakness in the hands and feet — because IgM can react against nerve tissue. Cold-triggered symptoms in the fingers and toes, or skin changes, occur in a minority. These features can be the first clue to WM.
These symptoms have many ordinary causes and most are not WM. But symptoms that are new, persistent and unexplained — especially with a raised blood protein — should be checked. Speak to a CION haematologist if you have these signs or a confirmed diagnosis.
Because WM is rare and slow-growing, the biggest risk is a rushed, one-size-fits-all decision. CION's approach is measured and evidence-led.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just found out you have Waldenström macroglobulinaemia, unsure whether to treat or monitor, or want a second opinion before starting? CION's haematology team is here.
Confirming WM — and telling it apart from other B-cell conditions such as small lymphocytic lymphoma or marginal zone lymphoma — takes a step-by-step pathway. CION delivers the blood work, bone-marrow examination, immunophenotyping and imaging directly, following NCCN and ESMO standards.
A full blood count checks for anaemia and low platelets. Serum protein electrophoresis and immunofixation detect and measure the monoclonal IgM protein — the hallmark of WM. If IgM is very high, blood viscosity is measured to assess the risk of hyperviscosity. Kidney and liver function and beta-2 microglobulin are also checked as prognostic markers.
A bone-marrow biopsy is central to the diagnosis. It shows the lymphoplasmacytic cells infiltrating the marrow, and immunophenotyping confirms the B-cell markers (such as CD20) that define the disease. This is what distinguishes true lymphoplasmacytic lymphoma from other causes of a raised IgM.
Testing for the MYD88 mutation supports the diagnosis and informs treatment planning. A CT scan assesses lymph nodes, the spleen and any disease outside the marrow. Together these results build a complete picture, which the tumour board uses to decide whether treatment is needed now or whether monitoring is safer.
Not everyone with Waldenström macroglobulinaemia needs treatment straight away. NCCN and ESMO guidelines support active monitoring (watch-and-wait) for people who have no symptoms — and this can safely continue for years. Treatment is started when the disease causes problems such as significant anaemia, hyperviscosity, bulky disease or neuropathy. (Source: NCCN and ESMO clinical practice guidelines.)
Because WM is slow-growing, the goal is to control the disease and relieve symptoms — not to treat every raised IgM number. Every case is reviewed by CION's multidisciplinary tumour board first. Treatment is described here by mechanism; for specific drug names and schedules please see the Lymphoma Treatment in Hyderabad page.
For people with no symptoms, careful active monitoring — regular clinic reviews and IgM blood tests — is the standard, evidence-based approach and can continue for years. This avoids treatment side effects while the disease is stable, with a clear plan to step in when needed. It is a form of care that suits many indolent (slow-growing) lymphomas.
When treatment is needed, a common backbone is an anti-CD20 monoclonal antibody, often combined with alkylating chemotherapy. These target the abnormal B-cells and reduce IgM production. CION's medical oncology team delivers antibody and chemotherapy directly, with supportive care managed in-house.
Modern targeted therapy that blocks B-cell signalling pathways has become an important option in WM, and the MYD88 result can help predict how well it may work. These are oral treatments described by drug class only here; your specialist will discuss whether they suit your situation.
If the blood is dangerously thick, plasmapheresis rapidly removes excess IgM and relieves hyperviscosity while other treatment takes effect. For selected younger patients with relapsing disease, a stem-cell transplant may be considered — this is coordinated through accredited partner facilities, not delivered in-house.
Waldenström macroglobulinaemia is generally an indolent disease, and while it is usually considered treatable rather than curable, many people live well with it for many years — often a decade or more — with treatment given in phases as symptoms arise. The likely course is estimated using a prognostic index that combines age, IgM level, haemoglobin, platelet count and beta-2 microglobulin.
For context, published series place the long-term survival of many indolent B-cell lymphomas favourably compared with aggressive types — aggressive lymphomas such as DLBCL have been reported at roughly 60–70% survival in published series, while Hodgkin lymphoma is often reported around 80–90%. WM, being slow-growing, tends to follow a chronic course of control rather than a single cure-or-not outcome. These are published, attributed generalisations only, and figures vary a great deal by individual — your CION haematologist can explain what they mean for you.
Where WM behaves differently from expected — for example if it transforms to a more aggressive lymphoma, which happens in a minority — the plan is reassessed by the tumour board, much as with a follicular lymphoma transformation.
Because WM is rare and finely balanced, a second opinion is especially worthwhile in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around your disease, not a template — with transparent costs explained up front. Request your free second opinion or call 18002028726. You may also want to read about our lymphoma hospital in Hyderabad.
Get a free written second opinion from CION's haematology tumour board — especially valuable if you have no symptoms but have been advised to start treatment.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Waldenström macroglobulinaemia (WM) is a rare, slow-growing type of non-Hodgkin lymphoma. It is the clinical form of a disease pathologists call lymphoplasmacytic lymphoma — an abnormal growth of B-lymphocytes in the bone marrow that produce large amounts of an antibody called IgM. Because of this it is sometimes referred to as an IgM lymphoma. The excess IgM protein can thicken the blood and cause many of the symptoms. WM is indolent, meaning it usually grows over years rather than weeks, and many people live with it for a long time. For the wider picture of lymphoma care, see our lymphoma hub.
They are closely linked but not quite identical. Lymphoplasmacytic lymphoma is the pathology term for the underlying B-cell tumour seen in the bone marrow. Waldenström macroglobulinaemia is the specific — and most common — form of that disease in which the tumour cells produce a monoclonal IgM antibody. In everyday clinical use the two names are often used interchangeably. A small number of lymphoplasmacytic lymphomas produce a different antibody type or none at all, so they are not technically WM. Getting the exact label right relies on a bone-marrow biopsy and specialised testing, which is why an accurate diagnosis matters.
Many people have no symptoms at first and WM is found on a routine blood test. When symptoms do appear they come from two sources: the lymphoma itself and the thick IgM protein. Common features include tiredness from anaemia, weakness, night sweats, weight loss, and swollen lymph nodes or an enlarged spleen. When IgM levels are very high the blood can become thick — called hyperviscosity — causing headaches, blurred vision, nosebleeds, dizziness or confusion. Some people develop numbness or tingling in the hands and feet (peripheral neuropathy). Hyperviscosity symptoms should be assessed urgently. Speak to a CION haematologist if you have these signs.
Diagnosis combines blood tests and a bone-marrow examination. Blood work measures the IgM level (via serum protein electrophoresis and immunofixation), a full blood count, and viscosity if levels are high. A bone-marrow biopsy confirms the lymphoplasmacytic cells, and immunophenotyping checks B-cell markers such as CD20. Molecular testing for the MYD88 mutation — present in the large majority of WM cases — supports the diagnosis and helps guide treatment planning. Imaging (CT) assesses lymph nodes and the spleen. CION delivers the blood work, bone-marrow exam, immunophenotyping and imaging directly, following NCCN and ESMO diagnostic standards.
Because WM is slow-growing, not everyone needs treatment straight away. People with no symptoms are often placed on watch-and-wait monitoring, which can safely continue for years. Treatment starts when there are symptoms — significant anaemia, hyperviscosity, bulky disease or neuropathy. Options are described by mechanism and include anti-CD20 monoclonal antibody therapy, alkylating chemotherapy, and modern targeted therapy that blocks B-cell signalling. If the blood is dangerously thick, plasmapheresis can rapidly remove excess IgM. For specific drug regimens, see the Lymphoma Treatment in Hyderabad page. CION delivers chemotherapy, antibody and targeted therapy directly.
WM is generally an indolent (slow-growing) lymphoma and, while it is usually considered treatable rather than curable, many people live well with it for many years — often a decade or more — with treatment given in phases as needed. Outlook depends on age, the IgM and haemoglobin levels, and other blood markers combined in a prognostic index. Broadly, indolent lymphomas carry a more favourable long-term course than aggressive types such as DLBCL. These are published, attributed generalisations only — figures vary a great deal by individual. Your CION haematologist can explain what the numbers mean for your own situation.
WM is rare and its management is nuanced — over-treating an asymptomatic patient is as much a mistake as under-treating a symptomatic one. At CION, every case is reviewed by a multidisciplinary tumour board, so decisions on watch-and-wait versus treatment are made carefully. We arrange IgM monitoring, bone-marrow testing and the MYD88 molecular test in-house, and deliver chemotherapy, antibody and targeted therapy directly. Where a stem-cell transplant is appropriate, it is coordinated through accredited partner facilities. See our lymphoma doctors and lymphoma hospital pages, or book a free consultation.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.